When should an iron infusion be given to a menstruating woman whose ferritin remains 14 ng/mL after six months of oral iron therapy?

When to Use Iron Infusion for This Patient

This menstruating woman with ferritin of 14 ng/mL after 6 months of oral iron therapy has failed oral treatment and should receive intravenous iron now. 1

Rationale for IV Iron

Your patient meets clear criteria for IV iron based on 2024 AGA guidelines, which explicitly state: "Intravenous iron should be used if the patient does not tolerate oral iron, ferritin levels do not improve with a trial of oral iron, or the patient has a condition in which oral iron is not likely to be absorbed." 1

After 6 months of oral iron, her ferritin remains at 14 ng/mL—well below the target of 50 ng/mL (regardless of sex) recommended by the 2024 expert consensus guidelines 2. This represents treatment failure.

Key Clinical Context

Heavy menstrual bleeding creates ongoing iron losses that require recognition of a fundamental principle: when there are ongoing losses (as explicitly noted for heavy menstrual bleeding in the guidelines), oral iron may be insufficient even when properly taken 2. The frequency of IV iron administration depends on the degree of blood loss 2.

Her ferritin of 14 ng/mL indicates:

• Depleted iron stores (goal is ≥50 ng/mL) 2
• Likely ongoing losses exceeding oral replacement capacity
• Risk for symptomatic iron deficiency even without anemia

Preferred IV Iron Formulations

Choose IV iron formulations that replace iron deficits with 1-2 infusions rather than multiple-dose regimens 1. The 2024 guidelines specifically recommend:

• Ferric carboxymaltose (FCM): up to 1000 mg per infusion
• Ferric derisomaltose (FDI): up to 1500 mg total dose infusion (the only FDA-labeled formulation for total dose infusion) 2
• Ferumoxytol: allows rapid, high-dose administration

These formulations are superior to iron sucrose, which requires multiple visits.

Expected Response and Monitoring

After IV iron administration 2:

• Hemoglobin should increase within 1-2 weeks
• Hemoglobin should rise by 1-2 g/dL within 4-8 weeks
• Check CBC and iron parameters (ferritin, TSAT) at 4-8 weeks post-infusion
  • Do NOT check iron parameters within 4 weeks—circulating iron interferes with assays
• Target ferritin: ≥50 ng/mL (in absence of inflammation)

Safety Considerations

All IV iron formulations have similar safety profiles 1. True anaphylaxis is very rare. Most reactions (occurring in up to 50% of patients) are complement activation-related pseudo-allergy (CARPA)—infusion reactions presenting as arthralgia, myalgia, or fever 3. These should be treated as infusion reactions, not true allergies.

Gastrointestinal side effects occur in essentially 100% of oral iron users 3, making IV iron actually better tolerated from a GI perspective.

Ongoing Management

Because she has heavy menstrual bleeding with ongoing losses, she will likely require repeat IV iron infusions. The frequency depends on her bleeding severity 2. Monitor ferritin every 6-12 months after initial repletion, or sooner if symptoms recur.

Critical pitfall to avoid: Do not continue oral iron indefinitely when ferritin fails to improve. Six months is more than adequate time to assess oral iron efficacy—most patients should show improvement within 8-10 weeks 4.

Address the underlying cause of heavy menstrual bleeding concurrently (gynecology referral for menorrhagia management, evaluation for bleeding disorders if appropriate).